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Abstract
Background: Brain capillary endothelial cells (BCECs) form the physiological basis of the blood-brain barrier (BBB).
The barrier function is (at least in part) due to well-known proteins such as transporters, tight junctions and
metabolic barrier proteins (e.g. monoamine oxidase, gamma glutamyltranspeptidase and P-glycoprotein). Our
previous 2-dimensional gel proteome analysis had identified a large number of proteins and revealed the major
role of dynamic cytoskeletal remodelling in the differentiation of bovine BCECs. The aim of the present study was
to elaborate a reference proteome of Triton X-100-soluble species from bovine BCECs cultured in the well-
established in vitro BBB model developed in our laboratory.
Results: A total of 215 protein spots (corresponding to 130 distinct proteins) were identified by 2-dimensional gel
electrophoresis, whereas over 350 proteins were identified by a shotgun approach. We classified around 430
distinct proteins expressed by bovine BCECs. Our large-scale gene expression analysis enabled the correction of
mistakes referenced into protein databases (e.g. bovine vinculin) and constitutes valuable evidence for predictions
based on genome annotation.
Conclusions: Elaboration of a reference proteome constitutes the first step in creating a gene expression database
dedicated to capillary endothelial cells displaying BBB characteristics. It improves of our knowledge of the BBB and
the key proteins in cell structures, cytoskeleton organization, metabolism, detoxification and drug resistance.
Moreover, our results emphasize the need for both appropriate experimental design and correct interpretation of
proteome datasets.
Background
The endothelia of different organs are remarkably het-
erogeneous but do present many common functional
and morphological features. Given the endothelium’s
strategic position between the blood and the tissues, this
cell layer (i) closely controls the transport of plasma
molecules (via bidirectional receptor-mediated and
receptor-independent transcytosis and endocytosis),
(ii) regulates vascular tone, (iii) synthesises and secretes
a wide variety of factors and (iv) is involved in the regu-
lation of inflammation, haemostasis, thrombosis and
immunity. It is now also generally accepted that the spe-
cific ultrastructure of capillaries in the brain, retina, kid-
ney and liver governs the specialized physiological
properties of these respective endothelia [1]. In the
brain, the blood-brain barrier (BBB) separates the brain
microvasculature from the peripheral microvasculature.
The BBB constitutes a physical and metabolic barrier
which tightly regulates blood-brain exchanges of ions,
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recruitment of immune cells prior to transfer to the
brain during inflammation [2-4].
In brain capillaries, the BBB is formed by endothelial
cells, which are surrounded by a tubular sheath of astro-
cytic end-feet. Pericytes are inserted into the basal mem-
brane (between the endothelium and the astrocytic
end-feet) [3]. This spatial cell layout and the resulting
astrocyte-endothelium communication induce the estab-
lishment and maintenance of the BBB [5-7]. Dysregula-
tion of these processes has been linked to the
pathogenesis of several human diseases [8].
In the brain, only blood capillaries are endowed with a
complete BBB phenotype [9]. Under physiological condi-
tions, the barrier function is performed by a number of
unique endothelial features, including (i) the lack of
fenestration, (ii) a decrease in the number of pinocytic
vesicles, (iii) the reinforcement of complex tight junc-
tions and (iv) the upregulated expression of metabolic
enzymes and plasma membrane transporters and recep-
tors [5]. The physiological consequences of endothelial
cell differentiation include an increase in the transen-
dothelial electrical resistance (due to a decrease in the
para- and transcellular endothelial permeability of ions
and low-molecular-weight hydrophilic compounds) and
are associated with marked polarization of the cerebral
endothelium [10,11]. In brain endothelial cells, the
plasma membrane acts as the controlling interface for
intracellular molecular signalling, the reinforcement of
tight junctions and molecular and cell transport between
the brain and the blood. The plasma membrane of brain
capillary endothelial cells (BCECs) has been extensively
studied and its membrane protein expression pattern
has been well defined [12]. The intracellular location of
certain proteins was shown to be essential for the estab-
lishment and maintenance of the BBB-related features
of BCECs. These intracellular locations are frequently
used as quality control criteria for in vitro BBB models.
Furthermore, it is known that the protein distribution
changes under pathological conditions [13,14]. Paradoxi-
cally, no dedicated studies in this field have been
reported. Moreover, the BBB’s metabolic proteome is
not well known and the cytosolic, nuclear and mito-
chondrial protein expression profiles have yet to be
extensively characterized. Therefore, the use of Triton
X-100 (known to poorly solubilise sparingly soluble pro-
teins [15]) appeared as the best way to select the
BCECs’ cytosolic subproteome in the present study.
Proteomics deals with the direct, large-scale determi-
nation of gene and cellular function at the protein level.
Recent successes have emphasized the role of mass
spectrometry-based proteomics as an essential tool in
molecular and cellular biology. Two-dimensional polya-
crylamide gel electrophoresis (2-DE) has become the
core technology for building proteomic databases, for
several reasons. Firstly, 2-DE can display thousands of
proteins and allows the relative quantification of any
given polypeptide. Secondly, the high-mass shifts caused
by one or more posttranslational modifications can be
characterized. Thirdly, digitized 2-DE images are conve-
nient, informative visual media for creating a web-based
database. Although 2-DE can (in theory) separate all
proteins, the technique has a number of drawbacks in
practice: (i) it is difficult to separate proteins with low
(< 10 kDa) or high (> 200 kDa) molecular weights,
(ii) the truly operational pI range is 3-11 and (iii) pro-
tein spots are frequently superposed. Complementary
approaches are often needed to overcome incompatibil-
ities between the 2-DE separation technique and the
physical-chemical properties of certain proteins of inter-
est. Liquid chromatography (LC) is an alternative (or a
complementary counterpart) to 2-DE.
On the basis of the in vitro BBB co-culture model devel-
oped in our laboratory [16], we have initiated a compre-
hensive proteomic approach based on the extractability of
proteins with Triton X-100. It uses a 2-DE/1D-LC combi-
nation to provide a detailed expression profile for the Tri-
ton X-100-soluble proteins expressed by bovine BCECs
(BBCECs) with the BBB phenotype. Here, we report on
the use of a high-throughput proteomics platform in the
2-DE identification of the most abundant Triton X-100-
soluble proteins, together with additional 1D-LC identifi-
cation. In addition to investigation of the correlation
between the identified proteins and BBB functions, the
present study was also designed to prime a comprehensive,
interactive, web-based proteomics database for BCECs
(2-DE images, comparative results, mass spectra, identifi-
cation scores, protein identities, protein functions, etc.), in
accordance with published guidelines [17,18].
Results
Verification of the re-induction of BBB properties
When isolated in vitro, primary BBCECs dedifferentiate
and lose their BBB properties. The latter can be restored
by 12 days of co-culture with glial cells [16]. We con-
firmed the re-induction of BBB properties by (i) measur-
ing an optimal value for the paracellular permeability
coefficient (Pe) and (ii) immunostaining the main tight
junction proteins (ZO-1, occludin and claudin-5). As
reported in the literature [19,20], the markers display a
pericellular distribution in differentiated BBCECs, which
contrasts with the uniform pattern for dedifferentiated
cells (data not shown). The BBCECs were harvested and
lysed according to the procedure described by Pottiez
et al. [21]. The Triton X-100-solubilised protein fraction
(representing 85% of the cell’s total protein) was then
subjected to either 2-DE or off-line 1D-LC tandem mass
spectrometry (MS/MS) analysis with a C18 column.
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Proteins of interest were subjected to 2-DE over a pH
range of 4-7 and a molecular weight range of 100-10
kDa. Four gels were prepared from four different filter
inserts. The 2-DE-separated proteins were stained with
either silver nitrate (to evaluate the reproducibility of
2-DE separation) or Coomassie brilliant blue (to per-
form the subsequent protein identification steps). Next,
384 of the most intense, best-resolved polypeptide spots
were automatically identified according to a Proteineer™-
workflow. Of the 384 excised spots, 215 (56%), were
unambiguously identified (Figure 1, in which the num-
bering corresponds to identified proteins; non-identified
proteins are not reported) and 198 were identified as
bovine proteins. Protein identifications were mainly
based on the peptide mass fingerprint (PMF) principle,
in which the Mascot 2.2 identification algorithm was
used to search the NCBInr and Swiss-Prot 57.7 data-
bases. The Mascot scores from the two databases were
similar for all but 9 proteins (indicated by an asterisk in
the Table S1, see Additional File 1). Moreover, 85 pro-
tein identities were confirmed by peptide fragmentation
fingerprinting (PFF). The 215 identified spots corre-
sponded to 130 distinct proteins (grouped together in
Table S1 in alphabetical order for convenience and
clarity). Interestingly, 8 protein spots (#42, 61, 90, 91,
113, 121, 127 and 147) were identified as containing two
proteins. Proteins with similar primary amino acid
sequences (e.g. ezrin-radixin-moesin complex proteins)
were well resolved by 2-DE and, despite their sequence
homologies, were more conveniently identified by PMF
than by PFF (data not shown).
One-dimensional liquid chromatography
Twenty μg of Triton X-100-solubilized proteins from
BBCECs were subjected to a 16-hour in-solution diges-
tion. The mixture of trypsin-generated peptides was
resolved by 1D-LC (on a C18 column with a linear
acetonitrile gradient), spotted and concomitantly co-
crystallised with a-cyano-4-hydroxycinnamic acid
(CHCA) matrix on a matrix-assisted laser desorption/
ionization (MALDI) target. The 380 spotted fractions
underwent automatic MS and MS/MS measurements.
Around 12000 compounds were detected in the MS
step and 3000 of these were subjected to MS/MS frag-
mentation. Due to the insufficient separative power of
the 1D-LC protocol, only a few peptides yielded a frag-
mentation pattern which was suitable for identification
(data not shown). Since 2D-LC technology is unavailable
in our laboratory, we developed a fractionation step (see
Material and Methods) for reducing protein heterogene-
ity prior to a 1D-LC analysis and for ensuring as many
protein identifications as possible. Each subfraction was
subjected to the previously described off-line 1D-LC
separation, in which around 3000 components were
MS-detected in the main fractions (F0, F25, F50 and
F75). Around 400 of these components were in-source
fragmented and 250 MS/MS spectra provided unambig-
uous protein identities. An average of 138 proteins were
identified from the F0 subfraction, with 235 in the F25
subfraction, 180 in the F50 subfraction, 185 in the F75
subfraction and only 9 from the F100 subfraction (Fig-
ure 2A). The latter figure also shows the proportion of
proteins specifically identified in only one fraction; frac-
tions F0, F25, F50 and F75 contained 41, 64, 22 and 35
fraction-specific proteins, respectively (black areas).
Moreover, 8 proteins were found in fractions F0 and
F25 (Figure 2A, diagonally hatched area), 23 proteins
were common to fractions F25 and F50 (Figure 2A, ver-
tically hatched area) and only 14 proteins were identified
in both fractions F50 and F75 (Figure 2A, horizontally
hatched area). Ultimately, no fewer than 363 proteins
(all listed in Table S2, see Additional File 2) were identi-
fied; 1D-LC MS/MS data are available in the European
Bioinformatics Institute’s PRIDE database [22] http://
www.ebi.ac.uk/pride under accession numbers 12825 to
12830. The data were converted using the PRIDE Con-
verter [23]. In all, 134 proteins (around 37%) were iden-
tified on the basis of only one peptide sequence, with
103 proteins identified from 2 MS-fragmented peptides
and 183 proteins identified from between 3 and 10 frag-
mented peptides. Nineteen proteins (such as vimentin,
titin, meosin, alpha-actinins 1 and 3, filamins A and B,
clathrin heavy chain 1, ATP synthase beta-subunit, vin-
culin, spectrin alpha chain (brain isoform) and
many tubulins (beta, beta-2C, beta-4, beta-5, etc.)) were
identified with 10 to 25 peptides sequenced. These
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Figure 1 Gel image from the 2-DE of Triton X-100-extracted
proteins from bovine brain capillary endothelial cells
displaying the blood-brain barrier properties. 215 protein
identities are reported on this 2-DE gel image and are summarized
in Table S1 (see Additional File 1).
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cell proteins or high-mass proteins. As shown in Figure
2B, a comparison of the protein sets identified respec-
tively by 2-DE or 1D-LC emphasizes the complementar-
ity of the two techniques; only 66 proteins (15%) were
identified by both techniques, whereas the great majority
of the proteins (302) were identified by 1D-LC.
Molecular functions of the identified proteins and their
involvement in biological processes
In order to classify all identified proteins according to
their molecular functions and the biological processes in
which they are involved, the correspond gene names
were generated using DAVID bioinformatics resources
http://david.abcc.ncifcrf.gov/home.jsp. All but 6 of the
430 genes were successfully classified according to the
PANTHER system http://www.pantherdb.org; ERP44,
ESYT1, Hist1h4a, NOP56, PLDB2 and TBA1B failed, for
unexplained reasons. The identified proteins displayed
11 molecular functions and are involved in 16 biological
processes (Figures 3A and 3B). As expected, most of the
identified species were metabolic proteins, binding pro-
teins or cell structure proteins (i.e. cytoskeletal proteins
or those involved in cytoskeleton formation and regula-
tion). Interestingly, we also identified proteins associated
with the transport and cell-cell communication (Figures
3A and 3B). Lastly (and as expected), 95% of the identi-
fied species were soluble (i.e. only 5% were plasma
membrane proteins) and 75% were intracellular proteins
(Figure 3C.).
The protein interference problem in a gel-free approach
In all, 2-DE identified 29 protein spots for vimentin (from
55 to 40 kDa and with pI values of between 5 and 4),
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Figure 2 Cross-analysis of protein lists. The sorting and cross-
analysis of protein lists was performed using nwCompare software.
(A) a comparative histogram of 1D-LC analyses of the main
fractions. Black areas: fraction-specific proteins; white areas: proteins
found in at least three different fractions; diagonal hatching: the
proportion of proteins common to the F0 and F25 fractions;
vertically hatching: the proportion of proteins common to F25 and
F50 fractions; horizontally hatching: the proportion of proteins
common to the F50 and F75 fractions. (B) a Venn diagram showing
the complementarity of the two approaches (in terms of the
proteins identified).
Molecular function
Biological process
A
B
Cellular components C
Figure 3 Chart of biological processes and molecular functions
inherent to the identified proteins. Classification of all identified
proteins was performed using the Protein Analysis Through
Evolutionary Relationships (PANTHER) classification system
http://www.pantherdb.org. Proteins are classified by expert
biologists into families and subfamilies of shared function, which are
then categorized by molecular function (A) and biological process
(B) ontology terms or in regard to the cellular components (C).
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with 24 mass-sequenced peptides and a sequence cover-
age of 56% (Figures 4A and 4B). In a shotgun approach,
proteins with similar primary amino acid sequences (e.g.
ezrin-radixin-moesin complex proteins) were identified
on the basis of their specific peptides. The more abun-
dant moesin was identified with 8 specific peptides,
whereas radixin and ezrin were identified with only two
and one specific peptides, respectively (Figure 4C).
Evidence for the existence of a 1134-amino acid
bovine vinculin
In the present study, we clearly identify vinculin with
1D-LC approach. However, the bovine forms (Q2PQT6-
1 and Q0VCE6) listed in UniprotKB (Figure 5A) were
not reported in the MASCOT result page (Figure 5B).
Fortunately (thanks to inter-species sequence homol-
ogy), the identifying result (Figure 5B) indicated that the
vinculin was from human, mouse and pig (with an iden-
tical cumulative Mowse score of 481 for all species). As
shown in Figure 5B, 12 mass-sequenced peptides
matched the amino acid sequence of human vinculin
(only 3 MS/MS-sequenced peptides display a low MAS-
COT score, due to low-quality fragmentation spectra).
In contrast, the MASCOT submission of PFF dataset to
the NCBInr database gave a positive match (Figure 5C)
for a predicted bovine vinculin (XP_001790344). The 12
mass-sequenced peptides were homogeneously distribu-
ted from the N-terminal to the C-terminal. This record
is derived from a genomic sequence (NW_001501727)
which was annotated using the GNOMON gene predic-
tion method and is supported by EST evidence. This
example serves as a reminder that to ensure high-quality
protein identification, the simultaneous submission of a
proteomics dataset to at least two protein databases is
as important as the use of a decoy database.
Discussion
The battle against the relentless progression of neurode-
generative disease, brain tumours and brain damage is a
public health priority. Although effective drugs have
been reported on the basis of in vivo research results,
drug targeting and delivery to the brain are still consti-
tute a challenge [24] one century after the discovery of
the BBB. In fact, the BBB is often the rate-limiting factor
in drug transport into the brain. Models of the BBB are
of major importance in efforts to expand our under-
standing of how the brain maintains its integrity and
Figure 4 Protein-level evidence of the expression of vinculin within bovine brain capillary endothelial cells. (A) A screen print from the
Mascot results page, showing the sequence coverage obtained for bovine vimentin. (B) A detailed overview of the MS/MS sequenced peptides
from bovine vimentin. (C) Sequence coverage for proteins displaying similar primary amino acid sequences: MOES_BOVIN, Moesin; RADI_BOVIN,
radixin; EZRI_BOVIN, ezrin (components of the ezrin-radixin-moesin (ERM) complex). The peptides common to all sequences are highlighted in
blue and the amino acid sequences which are specific for a given protein are shown in red.
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Page 5 of 11controls the inward and outward fluxes of endogenous
substances and drug compounds [9]. The development
of genomic and proteomic technologies has provided
several means of extending our knowledge of the BBB
and investigating additional routes for bypassing this
barrier [4].
Several BCEC-dedicated whole-cell or plasma mem-
brane proteomic approaches have been reported. Most
have been comparative studies designed to detect and
identify candidate proteins which are either differentially
expressed in two distinct conditions [25,26], involved in
a given physiological process [21,27] or expressed in
response to a particular stimulus [14,28-31]. Very few
studies have focused on sub-proteomes such as the pro-
tein content of the plasma membrane [12] or that of the
caveolae [32]. Although this type of targeted proteomic
study is essential for unravelling the molecular mechan-
isms governing the physiology and physiopathology of
the BBB’s endothelial cells, only small sets of protein
identities tend to be reported. Hence, large-scale deter-
minations of expression profiles for a given protein class
or cell compartment-related protein subset in BBB-
differentiated BCECs (relative to non-brain capillary
endothelial cells) have yet to be performed in any spe-
cies. The large-scale determination of BCEC protein
contents is a essential analytical step in gaining a better
understanding of the physiopathology of the BBB [33].
In the field of BBB research, proteomic analyses of
BCECs displaying BBB features and functions often
focus on proteins related to the tight junction, the
adherens junction, transport, drug resistance and the
regulation of the latter functions [34]. Most of the afore-
mentioned proteins are transmembrane proteins
anchored to the actin cytoskeleton by cytosolic proteins.
The importance of the intracellular location has been
well demonstrated [13]. In general, cytosolic proteins
are ignored - despite the fact that they are known to
p l a yar o l ei nm a n yB B Bf u n c t i o n s .O u rp r e s e n ts t u d y
Figure 5 Additional evidence for the expression of vinculin within bovine brain capillary endothelial cells. (A) A screen shot from
UniprotKB for bovine vinculin files. (B) A screen shot of the MASCOT results page following a search against the 57.7 UniprotKB database,
showing the 12 sequenced peptides matching the human vinculin amino acid sequence. (C); A screen shot from the MASCOT results page
showing the distribution of peptides over the full-length amino acid sequence of the predicted bovine vinculin (NW_001501727).
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proteins with possible relevance in BBB function. Firstly,
many of the identified proteins (27%) are related to
metabolic processes, such as the primary metabolism of
proteins, carbohydrates, nucleobases/nucleosides/nucleo-
tides, lipids, amino acids and their derivatives. We
consider that knowledge of the BCECs’ enzymatic equip-
ment constitutes a breakthrough. By way of an example,
levels of nitric oxide (known to modulate BBB perme-
ability) are related to the metabolism of arginine [35].
Oxidative stress is also an important modulator of BBB
permeability. In the present study, we showed that 31
oxidoreductase proteins are expressed by BCECs. Sec-
ondly, binding proteins represent around 30% of the
identified set. Of these, 32 are known to interact with
Ca
2+. It has been reported that both increases and
depletion of intracellular Ca
2+ may result in disruption
of intercellular junctions [36]. We also detected 104
nucleotide-binding proteins including 34 ribonucleopro-
teins and 38 RNA-binding proteins (ribosomal proteins,
heterogeneous nuclear ribonucleoproteins, splicing fac-
tors, eukaryotic translation initiation factors, tRNA
synthetase, etc.). Furthermore, 73 and 30 of the identi-
fied proteins are respectively ATP- and GTP-binding
proteins. Sixty-five proteins are described as having
molecular transport activities. Thirdly, structural com-
ponents account for around 20% of the proteins identi-
fied: half of the latter (n = 44) are cytoskeleton
components or cytoskeleton-associated proteins. In
addition to the presence of proteins like ERM com-
plexes, filamins, heat shock proteins, plectin, plastin 3,
alpha-actinins, cofilins, actin-capping proteins, spectrins
and tropomyosins, we report the expression of (i) junc-
tion plakoglobin (gamma catenin), a cytoplasmic protein
in soluble and membrane-associated forms and (ii) Talin
1, a crucial protein for reinforcement of integrin-
cytoskeleton bond and which binds vinculin with high
affinity [37]. Fourthly, 45 and 37 proteins reported in this
study are from mitochondria and endoplasmic reticulum
and which are involved not only in metabolism but also
in cell function. One example is the tumour necrosis fac-
tor receptor-associated protein 1 (TRAP-1) which pro-
tects cells from oxidative stress and apoptosis [38].
In fine, 293 of the identified proteins are phosphopro-
teins. Hence, Triton X-100-dependent protein extraction
may constitute a way of enriching the phosphoproteome
subset.
The creation of a dedicated proteomic database is the
best way of gathering and storing proteome information
but does require perfect sample traceability and strict
compliance with protein identification guidelines [17] in
order to avoid human error and, with a view to high
throughputs, guarantee the identity of proteins by redu-
cing the false positive rate as much as possible. Likewise,
the repeatability of protein identifications (at least triple
mass measurement of the same spot) must be carefully
checked and not postponed within the database to assure
the latter’s clarity and avoid obstruction (especially in the
case of publicly available databases). Due to the inherent
drawbacks of each analytical technique, the use of several
different approaches is the best way of ensuring the
broadest possible determination of proteins from a given
proteome. The recent development of commercially
available integrated solutions for high-throughput protein
identification (combining bio-informatics tools and auto-
mated sample handling with one or several mass spectro-
meters) constitutes a true source of progress; it saves
time, reduces the number of errors, increases the analyti-
cal throughput, centralizes the proteomic data and
enables more efficient comparison of datasets. Neverthe-
less, most in-house 2-DE, 1D-LC or 2D-LC databases are
not publicly available (for various reasons). As stated in a
recent review article [39,40], this situation can easily be
resolved by public, community-based solutions for the
long-term storage, management, sharing and comparison
of proteomic data, such as MIAPEGelDB [41], the
World-2DPAGE repository [42], PRIDE [43,44], GPMDB
[45], Peptideatlas [46] and PrestOMIC [47]. However, we
believe that a number of limitations remain.
The expansion of the LC-MS proteomic data storage
is significantly greater than that of the 2-DE proteomic
data. We believe that this can be explained by several
factors. Firstly, shotgun strategies are remarkably auto-
mated and powerful and clearly increase the overall data
throughput compared with 2-DE gel. Secondly, the web-
submission process in the proteomic repositories of
LC-MS proteomic data is now automatized, convenient
and secure (mainly thanks to the use of converters, such
as the PRIDE converter). Thirdly, web submission of
2D-PAGE proteomic data is still a manual, fastidious,
time-consuming step and is prone to human error. It
therefore requires more preparation steps (for the 2-DE
gel pictures, spot location data, MS data, MS protein
identification data, etc.); this situation clearly weakens
the commitment to communal sharing and prompts
researchers to overuse shotgun approaches.
The diversity of MS file formats is now handled well
by almost all proteomic data repositories, although some
proprietary file formats developed by MS manufacturers
are not yet supported. Therefore, proteomic data can be
submitted over the web via protein identification result
files, such as Mascot .dat files and SEQUEST result files.
However, whereas the MS/MS files used to create the
PFF are fully supported, the files corresponding to pro-
tein identifications based on PMF or combined PMF/
PFF protocols are not supported and the automatic
web-submission of the latter two files types is still not
possible. Overall, these are probably the main limiting
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proteomic datasets. We have contacted Dr Juan Antonio
Vizcaíno in the PRIDE group with a view to achieving
the parsing of PMF and combined PMF/PFF Mascot
data files from 2-DE experiments.
Protein databases are now so large that syntactic errors
are now acknowledged to be one of the reasons for
absent or false protein identifications. For example,
bovine vinculin is reported in UniprotKB under two
accession numbers Q2PQT6 and Q0VCE6 with 240 and
80 amino acids respectively. However, unmatured vincu-
lin displays an average of 1134 amino acids for isoform-1
and 1066 for isoform-2 from distinct species (human,
mouse, rat and pig). The NCBInr database reports a
bovine vinculin sequence (NW_001501727) derived from
a gene prediction process. Hence, on the basis of NCBInr
database and our LC-MS/MS data, we identified a 1134-
amino acid bovine vinculin; this shows that vinculin is
expressed in BBCECs in a form similar to those reported
in mammals. This type of de novo sequencing informa-
tion (i) provides direct evidence of the existence of listed
proteins in a given cell type in a given species, (ii) enables
the correction of certain mistakes reported in protein
databases (e.g. bovine vinculin) and (iii) can confirm pre-
dictions generated by genome annotation methods.
Vimentin identification is a classic example of the
technological bias inherent in each proteomic strategy.
Whereas 2-DE is able to distinguish between several
vimentin isoforms (resulting from post-translational
modifications), 1D-LC identifies only one protein.
Vimentin is one of the most prominent phosphoproteins
in various mesenchymal cells in which phosphorylation
is enhanced during cell division [48], when vimentin
filaments are significantly reorganized. Phosphorylation
also determines the assembly dynamics of vimentin
intermediate filaments [49]. Vimentin is also subject to
acetylation. In all, more than 50 isoforms are listed in
the protein databases. Consequently, vimentin cannot be
simply considered as the single protein reported by 1D-
LC. The 1D-LC identification of proteins with very simi-
lar primary amino-acid sequences is far from perfect
because it is based on the PFF corresponding to pro-
tein-specific peptides. This is known as the protein
interference problem [50] and, unfortunately, is still
ignored in too many cases. For soluble proteins > 20
kDa, the PMF obtained from 2-DE is more likely to
unambiguously distinguish between paralogous proteins.
Ultimately, combined PFF/PMF datasets are more discri-
minant and have a greater certainty of identification
because they are derived from in-gel separated proteins.
Conclusions
Our combination of 2-DE and 1D-LC approaches
enabled the first ever identification of about 430 Triton
X-100-soluble proteins (see Additional File 3) from
BBCECs displaying BBB characteristics. The information
on these protein identifications is now stored in in-
house databases and will be soon shared through the
PRIDE database for convenient comparison with proteo-
mic datasets from non-brain vascular endothelial cells.
Due to the extraction conditions, fewer than 5% of the
proteins corresponded to membrane-associated proteins.
More than 75% of the identified proteins display bind-
ing, catalytic or structural functions. Most identified
proteins were involved in metabolic and cellular pro-
cesses but transport and cell-cell communication pro-
cess accounted for almost 25% of the identified species.
The present study also emphasized the advantage of
inter-species sequence homology comparisons for pro-
tein identification in non-completely sequenced gen-
omes and highlighted the drifts and drawbacks
generated by the rapid, gel-free proteomic methods
(which nevertheless provide most of today’s data). In the
absence of a physiological, human in vitro BBB model,
the proteomics expression profile of BBCECs displaying
BBB properties is the first step towards the creation of
an anti-BBB antibody library which will greatly facilitate
large-scale, array-based screening of protein expression.
Methods
Materials
Heat-inactivated calf serum and horse serum were
bought from Hyclone Laboratories (Logan, UT, USA).
Glutamine and gentamycin were purchased from Bio-
chrom AG (Berlin, Germany). Serum, basic fibroblast
growth factor and Dulbecco’s Modified Eagle’sM e d i u m
(DMEM) were from GIBCO (Invitrogen Corporation,
Carlsbad, CA, USA). Six-well plates and Transwell
inserts were from Corning Inc. (New York, NY, USA).
The duracryl/bis-acrylamide solution was from Genomic
Solution (Proteomic Solutions, Saint-Marcel, France).
Immobilized pH gradient-ready strips were from GE
Healthcare (Amersham Bioscience, Orsay, France).
Trypsin digestion kits for the DP Proteineer™robot and
alpha-cyano-4-hydroxycinnamic acid were from Bruker
Daltonik GmbH (Bremen, Germany). All other reagents
were of analytical or electrophoresis grades.
Cell culture and the blood-brain barrier model
Primary cultures of mixed glial cells were made from new-
born rat cerebral cortex, as described by Booher and Sen-
senbrenner [51]. Briefly, glial cells were cultured in
DMEM supplemented with 10% (v/v) heat-inactivated foe-
tal calf serum, 2 mM glutamine and 50 μg/ml gentamycin.
Three weeks after seeding, the glial cell cultures were sta-
bilized and used for co-culture. Bovine brain capillary
endothelial cells were isolated and characterized as
described by Méresse et al.[ 5 2 ] .T h eB B C E C sw e r e
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an extracellular matrix (rat tail collagen) in DMEM sup-
plemented with 10% (v/v) heat-inactivated calf serum, 10%
(v/v) horse serum, 2 mM glutamine, 50 μg/ml gentamycin
and 1 ng/ml basic fibroblast growth factor.
Cell harvesting and protein extraction
The endothelial cells (8 × 10
5 cells) were harvested by
collagenase treatment (Clostridium histolyticum,S i g m a ,
Lyon, France) [21]. Briefly, the cells were treated at 37°C
for 40 min with 1.5 ml of a collagenase solution (0.1% w/
v). The collected cell materials were rinsed 3 times in
phosphate buffered saline (PBS), centrifuged 10 min at
500 g. The cell pellets were lysed in 200 μl of lysis buffer
[ T r i s / H C l1 0m M ,E D T A1m M ,T r i t o nX - 1 0 01 %( v / v ) ,
2-mercaptoethanol 0.1% (v/v) and protease inhibitors
(Roche Biomoleculars, Meylan, France)] and centrifuged
(13,500 g, 4°C, 45 min). The protein content of the Tri-
ton X-100 soluble and insoluble fractions was assessed
[53]. The supernatants were concentrated, desalted and
delipidated by overnight acid precipitation at -20°C.
Two-dimensional gel electrophoresis
After resolubilization in an isoelectrofocusing buffer (7
M urea, 2 M thiourea, 4% (v/v) CHAPS and 2% (v/v)
ampholytes), 300 μg of cytosolic proteins were subjected
to 2-DE on 24-cm length pH 4-7 IPG strips at 100,000
V and in the 10-100 kDa molecular mass range. The
IPG strips were passively and actively rehydrated for 7 h
and 9 h at 50 V. The pre-focusing and focusing proce-
dures were carried out at 50 mA/strip in 4 steps: 200 V
for 1 h, a gradient up to 1000 V for 1 h, a gradient up
to 10000 V for 6 h and, lastly, 10000 V for 4.5 h. The
IPG strips were wiped up and successively equilibrated
for 15 min with gentle shaking in 6 M urea, 20% (v/v)
glycerol, 2% (w/v) SDS, 93 mM TRIS-HCl pH 8.8 buf-
fers supplemented with 20 mM DTT and 100 mM
iodoacetamide and a trace of BPB, respectively. The
equilibrated strips were sealed on the top of the second-
dimension duracrylamide/bis-acrylamide gel (12% T,
2.6% C) with 0.5% (w/v) low-melting point agarose
(Biorad, Marnes-la-Coquette, France) in SDS running
buffer. Migration as a function of molecular weight was
performed in the Ettan DALTsix electrophoresis unit
(Amersham Bioscience) at 16 mA/gel for 30 min and
then at 32 mA/gel until the tracking dye reached the
anodic end. The proteins were stained with silver nitrate
[54] for image acquisition (with a freshly calibrated
Umax scanner (Amersham Biosciences, Orsay, France)
at 300 dpi using Labscan 3.0 software) and with colloi-
dal Coomassie Brilliant Blue for protein identification by
MALDI-TOF/TOF mass spectrometry.
Protein identification experiments after 2D-PAGE
Protein identifications from 2-DE gels were performed
using a Proteineer™workflow from Bruker Daltonik
GmbH. Colloidal Coomassie-blue-stained spots were
excised from gels with a spot picker (the Proteineer™-
spII) equipped with a 2 mm needle and placed into 96-
well microtitre plates. In-gel digestion and sample pre-
paration for MALDI analysis were performed according
to the manufacturer’s instructions using a digester/spot-
ter robot (the Proteineer™dp) and tryptic digest kits (the
DP 384 standard kit from Bruker Daltonik). Briefly, after
destaining of the gel plugs with 10 mM ammonium
bicarbonate and 50% acetonitrile in 10 mM ammonium
bicarbonate, protein spots were digested essentially
according to Shevshenko et al., 1996 [54]. Peptide were
extracted with acetonitrile: 0.1% TFA-acidified water
(1:1) and then mixed with an a-cyano-4-hydroxycin-
namic acid matrix (0.3 mg/ml in acetone:ethanol, 3:6 v/
v) on the MALDI target plate (AnchorChip™,B r u k e r
Daltonics). The molecular mass measurements were
performed in automatic mode using FlexControl™ 2.2
software on an Ultraflex™ II TOF/TOF instrument and
in reflectron mode for MALDI-TOF PMF or LIFT
mode for MALDI-TOF/TOF PFF. External calibration
over the 1000-3500 mass range was performed using the
[M+H]
+ monoisotopic ions of bradykinin 1-7, angioten-
sin I, angiotensin II, substance P, bombesin and adreno-
corticotropic hormone (clips 1-17 and clips 18-39) from
a peptide calibration standard kit (Bruker Daltonik).
Briefly, a 25 kV accelerating voltage, a 26.3 kV reflector
voltage and a 160 ns pulsed ion extraction were used to
obtain the MS spectrum. Each spectrum was produced
by accumulating data from 500 laser shots. Two precur-
sor ions per sample at most were chosen for LIFT-TOF/
TOF MS/MS analysis. Precursor ions were accelerated
to 8 kV and selected in a timed ion gate. Metastable
ions generated by laser-induced decomposition (LID)
were further accelerated by 19 kV in the LIFT cell and
their masses were measured in reflectron mode. Peak
lists were generated from MS and MS/MS spectra using
Flexanalysis™ 2.4 software (Bruker Daltonik). Database
searches with Mascot 2.2 (Matrix Science Ltd, London,
UK) using combined PMF and PFF datasets were per-
formed in the UniProt 57.7 and NCBInr databases via
ProteinScape 1.3 (Bruker Daltonik). A mass tolerance of
75 ppm and 1 missing cleavage site for PMF and an
MS/MS tolerance of 0.5 Da and 1 missing cleavage site
for MS/MS searching were allowed. Variable cysteine
carbamidomethylation and methionine oxidation were
also considered. The relevance of protein identities was
judged according to the probability-based Mowse score,
calculated with p < 0.05.
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Triton-soluble proteins from differentiated BBCECs are
extremely heterogeneous. To attenuate this phenomenon,
we fractionated the samples into 5 fractions of increasing
concentration in acetonitrile (0%, 25%, 50%, 75% and
100%). Following the tryptic digestion, nanoseparations
were performed on an U3000 nanoHPLC system (Dionex-
LC-Packings, Sunnyvale, CA, USA). After a conventional
pre-concentration step (C18 cartridge, 300 μm, 1 mm),
the peptide samples were separated on a Pepmap C18 col-
umn (75 μm, 15 cm) using an acetonitrile gradient from
5% to 12% over 20 minutes, 12% to 50% over 140 minutes
and 50% to 70% over 15 minutes and, lastly, 15 minutes in
70% of acetonitrile. The flow was set to 300 nl/min and
380 fractions were automatically collected every 30 sec-
onds on an AnchorChip™ MALDI target using a Protei-
neer™FC fraction collector (Bruker Daltonik). 2 μlo f
CHCA matrix (0.3 mg/ml in acetone:ethanol:0.1% TFA-
acidified water, 3:6:1 v/v/v) were added during the collec-
tion process. The MS and MS/MS mass measurements
were performed off-line using the Ultraflex™ II TOF/TOF
mass spectrometer, as described above. The apparatus
parameters were set to the values given above. Peptide
fragmentation was driven by Warp LC software (Bruker
Daltonik) according to the following parameters: signal-to-
noise ratio > 15, more than 3 MS/MS by fraction if the
MS signal was available, 0.15 Da of MS tolerance for peak
merge and the elimination of peaks which appears in
more than 35% of the fractions. The protein identification
was performed as described above.
Sorting protein lists and bioinformatics resources
The protein lists were compared using nwCompare soft-
ware [55]. All identified proteins were converted into
gene names with the DAVID bioinformatics resources
[56] before to be classification by the Protein Analysis
Through Evolutionary Relationships (PANTHER) classifi-
cation system. PANTHER is a unique resource that clas-
sifies genes by their functions, using published scientific
experimental evidence and evolutionary relationships.
Proteins are classified by expert biologists into families
and subfamilies of shared function, which are then cate-
gorized by molecular function and biological process
ontology terms [57,58].
Additional material
Additional File 1: Table S1. File reporting the complete gene list
identified from the 2D-PAGE experiment.
Additional File 2: Table S2. File corresponding to the complete gene
list identified from the LC-MS experiment.
Additional File 3: The complete gene list extracted from PANTHER
and corresponding to all identified proteins.
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